Inovio Pharmaceuticals, Inc.
INO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -44.1% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | 100% | -563.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -29,002.7% | -15,903.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -30,140.5% | -16,566.4% |
| EPS Diluted | -0.87 | -0.61 | -725.11 | -0.7 |
| % Growth | -42.6% | 99.9% | -103,487.1% | – |
| Operating Cash Flow | -$0 | -$21 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$21 | -$0 | -$0 |